Eudragit® E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD)

被引:43
|
作者
Leopold, CS [1 ]
Eikeler, D [1 ]
机构
[1] Univ Dusseldorf, Dept Pharmaceut Technol, D-40225 Dusseldorf, Germany
关键词
colon-specific drug delivery; inflammatory bowel disease; lag time; pH-controlled drug release;
D O I
10.3109/10611869808997884
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
During an attack of ulcerative colitis the colonic pH of normally 6.4-7.0 drops to values of 2.3-3.7. The objective of this study was to investigate an acid-soluble polymer (Eudragit(R) E) as coating material for multiple units (mini tablets) with regard to its ability to allow drug release only under the acidic conditions of the inflamed colon. Mini tablets (empty set 3 mm) containing 20% (w/w) of the model drug dexamethasone with or without the mucoadhesive swelling agent carbomer 934 (neutralized) were coated in a small coating pan with different amounts of an organic solution of Eudragit(R) E leading to coating thicknesses of 150-400 mu m Drug release from the Eudragit(R) E-coated cores at pH 2.0-5.0 starts after 10-50 min due to the rapid dissolution of the Eudragit(R) E film. At pH 6.8 lag times of drug release depend on the composition of the cores and the thickness of the coating film. In the case of the carbomer-containing cores drug release is induced by disruption of the coating film due to swelling of the cores and lag limes (up to 20 h) increase overproportionately with increasing coating thickness, With no swelling agent in the cores drug release at pH 6.8 is delayed due to the low erosion/dissolution rate of Eudragit(R) E. Lag limes of drug release (up to 33 h) increase in a linear manner with increasing coating thickness, Thus, Eudragit(R) E, protected against dissolution in the stomach by an enteric coating, ls a suitable coating polymer for drug release in acidic regions such as the inflamed colon.
引用
收藏
页码:85 / 94
页数:10
相关论文
共 22 条
  • [1] Controlled drug release for inflammatory bowel disease (IBD)
    Asha, D.
    Jeganath, S.
    Bupesh, G.
    Sahoo, U. K.
    Bhaskar, M.
    Pandian, K.
    BIOINFORMATION, 2020, 16 (07) : 513 - 524
  • [2] Biodegradable microparticles as a two-drug controlled release formulation:: a potential treatment of inflammatory bowel disease
    Lamprecht, A
    Torres, HR
    Schäfer, U
    Lehr, CM
    JOURNAL OF CONTROLLED RELEASE, 2000, 69 (03) : 445 - 454
  • [3] Chitosan-Derived Nanocarrier Polymers for Drug Delivery and pH-Controlled Release in Type 2 Diabetes Treatment
    Guo, Shanshan
    Li, Hua
    JOURNAL OF FLUORESCENCE, 2024,
  • [4] Biologics for the Treatment of Patients with chronic inflammatory Bowel Disease (IBD): Therapy Continuity and associated Drug Costs
    Groth, Antje
    Wilke, Thomas
    Brandes, Alina
    Ratsch, Boris
    Fuchs, Andreas
    Deiters, Barthold
    Bokemeyer, Bernd
    INTERNIST, 2018, 59 : S70 - S70
  • [5] Controlled release of sulfasalazine loaded amidated pectin microparticles through Eudragit S 100 coated capsule for management of inflammatory bowel disease
    Deshmukh, Rohitas
    Harwansh, Ranjit K.
    Das Paul, Swarnali
    Shukla, Rishikesh
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2020, 55
  • [6] Coatless alginate pellets as sustained-release drug carrier for inflammatory bowel disease treatment
    Ramli, Siti Hajar Md
    Wong, Tin Wui
    Naharudin, Idanawati
    Bose, Anirbandeep
    CARBOHYDRATE POLYMERS, 2016, 152 : 370 - 381
  • [7] Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease
    Oshi, Murtada A.
    Naeem, Muhammad
    Bae, Junhwan
    Kim, Jihyun
    Lee, Juho
    Hasan, Nurhasni
    Kim, Wooseong
    Im, Eunok
    Jung, Yunjin
    Yoo, Jin-Wook
    CARBOHYDRATE POLYMERS, 2018, 198 : 434 - 442
  • [8] Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis
    Gross, Volker
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (07) : 1257 - 1265
  • [9] A mesoporous polydopamine-derived nanomedicine for targeted and synergistic treatment of inflammatory bowel disease by pH-Responsive drug release and ROS scavenging
    Guan, Haidi
    Xu, Zhongwei
    Liu, Qinghua
    Tan, Qianshan
    Chen, Yihui
    Chen, Shuaishuai
    Wu, Jingfeng
    Wang, Fengchao
    Zhang, Jixi
    Sun, Lihua
    Xiao, Weidong
    MATERIALS TODAY BIO, 2023, 19
  • [10] Eudragit E PO as a Complementary Material for Designing Oral Drug Delivery Systems with Controlled Release Properties: Comparative Evaluation of New Interpolyelectrolyte Complexes with Countercharged Eudragit L100 Copolymers
    Moustafine, R. I.
    Bukhovets, A. V.
    Sitenkov, A. Y.
    Kemenova, V. A.
    Rombaut, P.
    Van den Mooter, G.
    MOLECULAR PHARMACEUTICS, 2013, 10 (07) : 2630 - 2641